Close Menu

This article has been updated from a previous version to include comments made by Veracyte executives during the company's earnings call.

NEW YORK – Genomic testing firm Veracyte reported after the close of the market Tuesday that its third quarter 2019 revenues grew 32 percent year over year.

For the three months ended Sept. 30, the South San Francisco, California-based firm reported total revenues of $31.0 million, compared to $23.5 million in Q3 2018, beating analysts' average estimate of $30.1 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.